Reviewed issue profile

Healthcare, Prescription Drugs and Medicare

This page groups reviewed filings reported under Health Issues, Pharmacy, and Medicare/Medicaid codes. It shows disclosed activity without assigning support, opposition, motive, or policy impact.

Data retrieved through Sep 4, 2026 · Content reviewed Sep 4, 2026

Editorial illustration representing healthcare, prescription drugs, and Medicare.
Lobbying disclosure

Definition and selection boundary

A normalized Gov Influence group for reviewed filings that use HCR, PHA, or MMM. Source descriptions may state narrower subtopics, but the page does not infer a position from those terms.

Official source codes included in this normalized issue
Code and official labelDistinctionOrganizationsFilingsActivities
HCRHealth IssuesHealth Issues records41717
PHAPharmacyPharmacy records233
MMMMedicare/MedicaidMedicare/Medicaid records377

Included

  • Include a retained filing once when any activity reports HCR, PHA, or MMM.
  • Keep Health Issues, Pharmacy, and Medicare/Medicaid activities separated by their official source code.

Excluded

  • Do not include a filing merely because an organization operates in healthcare or serves older adults.
  • Generic references to benefits, consumers, budgets, or government programs are too broad without a reviewed HCR, PHA, or MMM activity.

Classification method: Only filings carrying the reviewed Health Issues, Pharmacy, or Medicare/Medicaid LDA issue codes enter this grouping.

Site calculation

Matched collection by quarter

Counts use retained, exact-alias filings and count a filing once on this issue page even when more than one included code appears in it.

Matched organizations and filings in Q1–Q2 2026
Reporting quarterOrganizationsFilings
2026 Q1410
2026 Q249

14 of this page’s 19 filing matches also appear in at least one other normalized issue. That overlap is expected because a filing can report several official codes; issue totals must not be added together as if they were unique records.

Organization reporting patterns

Compare the reported HCR, PHA, and MMM patterns and preserve narrower source-language subtopics without interpreting support or opposition. Dollar fields preserve reporting state; partial means at least one applicable filing did not provide a numeric value.

Organization-level issue matches with expense and income bases kept separate
OrganizationQuarterFilingsSelf-reported expensesOutside-registrant income
AARP2026-Q13$3,830,000$70,000
AARP2026-Q22no applicable records$70,000
Amazon2026-Q12$4,380,000$80,000
Amazon2026-Q22$4,360,000$80,000
Boeing2026-Q11$2,450,000no applicable records
Boeing2026-Q21$2,770,000no applicable records
Pfizer2026-Q14$4,420,000$270,000
Pfizer2026-Q24$1,880,000$270,000

Self-reported organization expenses are never added to outside-registrant income. A filing may also cover matters outside this normalized issue, so its organization-level amount is contextual and is not allocated to a code, description, bill, or outcome.

Representative original descriptions

One deterministic example is selected for each included code by organization name and filing ID. The text is preserved from the filing and is illustrative, not a ranking.

HCR · AARP · 2026 Q2

Rural healthcare access issues for seniors

PHA · AARP · 2026 Q1

S. 1040, the Drug Competition Enhancement Act. S. 1041, the Affordable Prescriptions for Patients Act. S. 2620, the Reforming Evergreening and Manipulation that Extends Drug Years Act or the REMEDY Act. S. 2658, the Medication Affordability and Patent Integrity Act. S. 1095, the Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act. S. 1096, the Preserve Access to Affordable Generics and Biosimilars Act. S. 1784/H.R. 4191, the Mapping America's Pharmaceutical Supply Act or the MAPS Act. No bill number. Lifetime prescription drug price increases. No bill number. Discussed Medicare drug price negotiation. No bill number. Discussed Medicare Part D. No bill number. Discussed international reference pricing. No bill number. Discussed prescription drug supply chain vulnerabilities. No bill number. Discussed Most Favored Nation prescription drug model and GLOBE model. No bill number. Discussed Medicare Part D/ Most Favored Nation prescription drug model, GUARD. No bill number. Discussed pharmacy benefit manager reforms. No bill number. Discussed proposed Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, and Medicare Cost Plan Program. No bill number. Discussed prescription drugs.

MMM · AARP · 2026 Q1

S. 3439/H.R. 6735, Connecting Caregivers to Medicare Act. S. 1227/H.R. 2491, Alleviating Barriers for Caregivers Act. P.L. 119-21, the One Big Beautiful Bill Act. H.R. 6766/S. 3492, the Essential Caregivers Act. H.R. 7966/S. 4118, Hospice Care Accountability, Reform, and Enforcement (Hospice CARE) Act. H.R. 7618, Stopping Addiction and Falls for the Elderly (SAFE) Act. S. 2237/H.R. 4313, Hospital Inpatient Services Modernization Act. H.R. 8100, Safe Staffing Saves Lives Act. S. 3886, Nurses Belong in Nursing Homes Act. H.R. 7966/S. 4118, Hospice Care Accountability, Reform, and Enforcement (Hospice CARE) Act. S. 3886, Nurses Belong in Nursing Homes Act. No bill number. Discussed Medicare payment models. No bill number. Discussed Medicare waste, fraud, and abuse. No bill number. Discussed health technology, data security, enrollee accounts, and access. No bill number. Discussed Medicaid and waste, fraud, and abuse. No bill number. Discussed Medicaid community engagement requirements and Data Strategy for Family Caregiver Verification. No bill number. Discussed nursing home staffing standards, safety, and quality. No bill number. Discussed nursing home transparency and ownership requirements. No bill number. Discussed home health, hospice, and long-term care. No bill number. Discussed Medicare Advantage. No bill number. Discussed the Medicare Prescription Drug Benefit Program. No bill number. Discussed the Medicare Cost Plan Program. No bill number. Discussed Medicare Advantage Capitation Rates. No bill number. Discussed Medicare Part C and Part D payment policies. No bill number. Discussed Medicare Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH). No bill number. Discussed AI tools for Medicare Experience modernization. No bill number. Discussed Medicare Advantage provider networks. No bill number. Discussed fraud in Medicare and Medicaid. No bill number. Discussed long-term services and supports. No bill number. Discussed home and community-based services. No bill number. Discussed the Money Follows the Person Rebalancing Demonstration Program. No bill number. Discussed Medicaid home and community-based services (HCBS) spousal impoverishment protections. No bill number. Discussed the direct care workforce. No bill number. Discussed family caregiver exemption from Medicaid community engagement requirements. No bill number. Discussed falls prevention. No bill number. Discussed age-friendly communities. No bill number. Discussed health at home. No bill number. Discussed the National Strategy to Support Family Caregivers. No bill number. Discussed the Older Americans Act reauthorization. No bill number. Discussed Medicaid HCBS waivers. No bill number. Discussed the health care workforce.
Context only

Reviewed bill context

A bill appears only when original matched filing language explicitly names it or an existing approved contextual-link record supplies the basis. A mention does not show support, opposition, coordination, effect, or causation.

S 933

2 matched filings explicitly name this bill in original source wording.

Interpretation

What this page cannot show

  • Whether an organization favored or opposed a health, drug, Medicare, or Medicaid policy.
  • Patient, price, access, coverage, or health-outcome effects.
  • Healthcare activity outside the selected records and reporting period.
  • Code matches, descriptions, timing, organizations, reported amounts, and bill references do not establish influence, coordination, motive, wrongdoing, or causation.
Show 19 matched source records

Continue exploring

organization

Boeing

Boeing provides a focused view of federal lobbying disclosures involving defense, aerospace, aviation, and procurement, alongside separately labeled legislative, political-finance, and federal-award context.

organization

Amazon

Amazon.com Services LLC offers a source-backed view of disclosed federal activity spanning technology, labor, consumer, trade, and other policy areas without treating separately named Amazon entities as automatic matches.

organization

Pfizer

Pfizer Inc.'s reviewed disclosures support a focused profile of reported federal activity involving health, Medicare and Medicaid, pharmacy, tax, trade, and related policy areas.

organization

AARP

AARP's reviewed disclosures cover health, Medicare and Medicaid, pharmacy, retirement, tax, telecommunications, and other issues affecting older Americans.

bill

S 933

NASA Transition Authorization Act of 2025